Monitin Ltd. entered into a merger agreement to acquire Nextgen Biomed Ltd (TASE:NXGN-M) in a reverse merger transaction for approximately ILS 70.5 million on January 12, 2020. Pursuant to the terms, Nextgen Biomed will acquire Monitin and will issue 260.9 million shares constituting 90% of the issued share capital as a consideration. The transaction is subject to receipt of all customary approvals. Monitin Ltd. cancelled the acquisition of Nextgen Biomed Ltd (TASE:NXGN-M) in a reverse merger transaction on February 17, 2020. The deal has been cancelled due to personal issued concerning Monitin’s controlling shareholder, Weizman Shiri.